Neogen Revenue Growth Rates (NEOG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neogen Corporation  (NASDAQ: NEOG)
 

NEOG's Revenue Growth by Quarter and Year

Neogen's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NEOG/growth
https://api.csimarket.com/api/v1/companies/NEOG/fundamentals
https://api.csimarket.com/api/v1/companies/NEOG/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NEOG Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter May -
3rd Quarter February -
2nd Quarter November -
1st Quarter August 222.90
FY 222.90

NEOGs Annual Revenue
Neogen's Revenue in the fiscal year 2026 $ 870.60 millions
Neogen's Revenue in the fiscal year 2025 $ 894.38 millions
Neogen's Revenue in the fiscal year 2024 $ 923.90 millions
Neogen's Revenue in the fiscal year 2023 $ 821.96 millions
Neogen's Revenue in the fiscal year 2022 $ 527.16 millions




NEOG Revenue first quarter 2026 Y/Y Growth Comment
Neogen Corporation reported Revenue growth of 6.67% year on year in the first quarter 2026, to $ 222.90 millions, this is lower than Neogen Corporation's recent average Revenue increase of 12.4%.

Looking into first quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Neogen Corporation' s Revenue increase of 6.67% ranks overall at the positon no. 2117 in the first quarter 2026.


NEOG Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter May -
3rd Quarter February -
2nd Quarter November -
1st Quarter August 6.67 %
FY   -

Financial Statements
Neogen's first quarter 2026 Revenue $ 222.90 millions NEOG's Income Statement
Neogen's first quarter 2025 Revenue $ 208.97 millions Quarterly NEOG's Income Statement


NEOG Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter May -
3rd Quarter February -
2nd Quarter November -
1st Quarter August -1.17 %
FY (Year on Year)   -


Back to NEOG Growth rate Comparisons >> Back to NEOG Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #313
Overall #2117

Revenue Y/Y Growth Statistics
High Average Low
76.25 % 12.4 % -5.17 %
(Aug 31 2023)   (Feb 28 2026)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #313
Overall #2117
Revenue Y/Y Growth Statistics
High Average Low
76.25 % 12.4 % -5.17 %
(Aug 31 2023)   (Feb 28 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Neogen's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
73.81 % 3.08 % -8.84 %
(Nov 30 2022)  


NEOG's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Neogen Corporation disclosed decrease in Revenue from the fourth quarter by -1.17% to $ 222.90 millions, from $ 225.54 millions achived in the previous reporting period.

But that's not important problem, as Neogen's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Neogen's Revenue growth quarter on quarter, overall rank is 2005.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #254
Overall #2005
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #4
Healthcare Sector #254
Overall #2005
Revenue Q/Q Growth Statistics
High Average Low
73.81 % 3.08 % -8.84 %
(Nov 30 2022)  


NEOG's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2026 Neogen Corporation disclosed decrease in Revenue from the fourth quarter by -1.17% to $ 222.90 millions, from $ 225.54 millions achived in the previous reporting period.

But that's not important problem, as Neogen's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Neogen's Revenue growth quarter on quarter, overall rank is 2005.


Neogen's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Aug 31 2026)		 12 Months Ending (May 31 2026) 12 Months Ending (Feb 28 2026) 12 Months Ending (Nov 30 2025) 12 Months Ending (Aug 31 2025)
Cumulative Revenue 12 Months Ending $ 884.12
Y / Y Revenue Growth (TTM) -0.26 %
Year on Year Revenue Growth Overall Ranking # 2874
Seqeuential Revenue Change (TTM) 1.6 %
Seq. Revenue Growth (TTM) Overall Ranking # 2709


Cumulative Revenue growth Comment
Neogen showed decline, but improvement compare to trailing twelve month Revenue decrease in May 31 2026. If the fiscal year would end in Aug 31 2026, Neogen's annual Revenue improvement would be -0.26% year on year to $884 millions.

In the Healthcare sector 403 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2874, from total ranking in previous quarter at 2892.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 404
Overall # 2874

Revenue TTM Y/Y Growth Statistics
High Average Low
72.88 %
 12.44 %
-3.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 385
S&P 500 # 2709
Cumulative Revenue growth Comment
Neogen showed decline, but improvement compare to trailing twelve month Revenue decrease in May 31 2026. If the fiscal year would end in Aug 31 2026, Neogen's annual Revenue decline would be -0.26% year on year to $884 millions.

In the Healthcare sector 403 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2874, from total ranking in previous quarter at 2892.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 404
Overall # 2874

Revenue TTM Y/Y Growth Statistics
High Average Low
72.88 %
12.44 %
-3.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 385
S&P 500 # 2709




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NEOG's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Aug 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Aug 31 2026
Angiodynamics Inc 8.09%$ 8.093 millions
Neogen Corporation6.67%$ 6.666 millions


About Neogen Revenue Growth Rates (NEOG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Neogen Corp (CIK 711377).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-416954
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Neogen Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.